Fig. 3: Targeting nEGFR activates the tumor immune microenvironment.
From: Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
ϯTumors from the WAP-TGFα female mice treated with cSNX1.3 (n = 6) or cPTD4 (n = 5) were fixed and paraffin embedded. The embedded tissue was used for NanoString analysis. a Change in tumor volume per day of mice treated with cSNX1.3 or cPTD4, ±SEM. Statistics were analyzed using an unpaired t test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. b Heatmap demonstrating cell type score for each cSNX1.3 and cPTD4 sample. Red represents upregulation and blue represents downregulation of gene expression. c Volcano plot showing the differentially expressed genes in cSNX1.3 vs. cPTD4. Blue dots represent downregulated genes (4) with a log2FC < 0.5 and red dots represent upregulated genes (n = 41) with a log2FC > 0.5. Scatter plots showing Log2 normalized expression of genes found to be ϯϯsignificant (Padj ≤ 0.05) between cSNX1.3 and cPTD4. ϯ11 tumors that started from the ≥100 mm3 arm of the study (left) were used for NanoString analysis. ϯϯUnpaired t test; correction for multiple testing using Benjamini-Hochberg method in R.
